A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)
Active, not recruiting · NCT06517940
Conditions: Retinitis Pigmentosa
At a glance
- Research payments reported, 2025
- $104,087
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 12
About the trial
- Sponsor
- Sumitomo Pharma America, Inc.
- Dates
- Started 2024-10-03; completion 2026-04-24
- Results posted
- Not yet
The natural history in individuals with severe retinitis pigmentosa (RP) is variable and there remains an unmet need to better understand disease progression in this population. The goal of this study is to determine which visual assessments individuals with RP and low visual acuity can reliably perform and to evaluate the annual decline of visual function in severe RP.
From ClinicalTrials.gov, last updated 2026-02-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sumitomo Pharma America, Inc. reported $104,087 in research payments for this study in 2025 (30 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.